Concepedia

Kin-Ming Lo

KL

33

Publications

4.4K

Citations

29

H-Index

1983

Active since

Affiliations

Harvard University(Current)

Lexicon Pharmaceuticals (United States)

Ono Pharmaceutical (United States)

Merck Serono (Italy)

Merck (Germany)

Kin-Ming Lo is an author at Harvard University specializing in medicine, immunology, and tumor microenvironment.

ORCID

Top concepts

Publications per year

1983–2022

33

Publications

33

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

Gabriele Bergers, Kashi Javaherian, Kin-Ming Lo et al. · Science · 1999 · 987 citations

, , +15

Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis

Karen S. Moulton, Khashayar Vakili, David Zurakowski et al. · Proceedings of the National Academy of Sciences · 2003 · 650 citations · Full text

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Yan Lan, Dong Zhang, Chunxiao Xu et al. · Science Translational Medicine · 2018 · 474 citations

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†

Jonathan H. Davis, Christel Aperlo, Yue Li et al. · Protein Engineering Design and Selection · 2010 · 185 citations · Full text

Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion

Yan Lan, Mahmoud Moustafa, Maximilian Knoll et al. · Cancer Cell · 2021 · 178 citations · Full text

Rows per page

1–5 of 33